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Calpains are Ca2þ-regulated proteolytic enzymes that are involved in a variety of biological phenomena.
Calpains process substrates by limited proteolysis to modulate various protein functions in the cell, and
are thus called “modulator proteases.” CAPN3, previously called p94 or calpain-3, has unique features
that are not found in any of the other 14 human calpains, or even in other proteases.
For instance, CAPN3 undergoes extremely rapid and exhaustive autodegradation. CAPN3 is also the
ﬁrst (and so far, the only) intracellular enzyme found to depend on Naþ for its activation. CAPN3 has both
proteolytic and non-proteolytic functions. It has the interesting distinction of being the only protease,
other than a few virus proteases, with the ability to regain protease function after its autolytic dissoci-
ation; this occurs through a process known as intermolecular complementation (iMOC). Gene mutations
causing CAPN3 defects are responsible for limb-girdle muscular dystrophy type 2A (LGMD2A).
Unusual characteristics of CAPN3 have fascinated researchers, but have also hampered conventional
biochemical analysis. In this review, we describe signiﬁcant ﬁndings about CAPN3 from its discovery to
the present, and suggest promising avenues for future CAPN3 research.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Proteases are enzymes that hydrolyze peptide bonds, which are
otherwise highly stable under physiological conditions. Proteases
are themselves proteins, and proteolyze themselves to various ex-
tents; this process is called autolysis. The calpain CAPN3 (previ-
ously called p94, nCL-1, nCANP, and calpain-3) has such strong
autolytic activity that it degrades itself within minutes, leaving
researchers wondering whether such a protease can have any
physiological function, and how to go about studying such an
ephemeral molecule.
Despite its rapid autolytic process, CAPN3 has many important
functions, and its idiosyncrasies have drawn a growing number of
enthusiastic researchers. We here review the history of CAPN3
research, and introduce unusual characteristics of CAPN3 from the
perspective of structureefunction relationships. (Although CAPN3
is involved in postmortem meat quality and tenderization in some
animals [18e31], this review focuses on physiological and patho-
physiological functions of CAPN3.)2. The discovery of CAPN3
2.1. Discovery of the calpain family
In January of 1964, calpain (calcium-dependent papain-likeprotease; Clan CA, family C02; EC3.4.22.17) was described for the
ﬁrst time by Gordon Guroff [35]. The primary structure of the cal-
pain catalytic subunit was determined in 1984 [37], revealing a
multi-domain structure consisting of a cysteine protease domain,
now called a Calpain-type cysteine Protease conserved (CysPc)
domain [38e40], a Calpain-type Beta-SandWich (CBSW) domain,
previously called a C2-domain-like (C2L) domain, and a Penta E-F
hand (PEF) [41] domain (Fig. 1). The CysPc domain is composed of
two Protease Core subdomains (PC1 and PC2). Until 1989, most
calpain studies focused on calpain-1 (previously called m-calpain,
mCANP, or calpain-I) and calpain-2 (m-calpain, mCANP, or calpain-
II). Thus, these calpains are called “conventional” calpains. The
terms calpain-1 and calpain-2 are now reserved for the active en-
zymes, which are heterodimers consisting of a larger ca. 80-kDa
catalytic subunit, either CAPN1 (previously called mCL or m80K) or
CAPN2 (mCL orm80K), and a smaller ca. 28-kDa regulatory subunit,
CAPNS1 (30K) (Fig. 1).
The name “calpain,” ﬁrst used by Takashi Murachi in 1981 [42],
was proposed to be the ofﬁcial name of this protease family in 1990
by Koichi Suzuki [43]. Mammals have more than a dozen calpain
genes (Table 1), half of which are predominantly expressed in
speciﬁc tissues or organs. Calpains with the same domain structure
as CAPN1 and CAPN2 are called “classical” calpains, and the rest are
“non-classical” (Fig. 1). Genetics studies have revealed that indi-
vidual calpains have important and widely divergent physiological
Table 1
Known calpainopathies and the responsible calpains. CAPNx and Capnx indicate human and mouse genes, respectively.
Gene Expression preference Deﬁciency phenotype References
Capn1 Most cells Platelet dysfunction [1]
Capn2 Most cells Embryonic lethal [2,3]
CAPN3, Capn3 Skeletal muscle Muscular dystrophy etc. [4e7]
CAPN5, Capn5 Most cells Vitreoretinopathy [8,9]
Capn6 Embryonic muscle Hypergenesis [10]
Capn7 Most cells U.I.a [12]
Capn8 Gastrointestinal tract Gastric ulcer [13]
Capn9 Gastrointestinal tract Gastric ulcer [13]
CAPN10 Most cells Type 2 diabetes [14]
Capn11 Testis U.I. [15]
Capn12 Hair follicle U.I. [17]
Capn13 Most cells N.I. [32]
CAPN14 Esophagus Eosinophilic Esophagitis [33]
CAPN15/SOLH Most cells N.I. [34]
Capn16/Adgb/C6orf103 Testis U.I. [36]
a U.I., under investigation; N.I., no information so far.
Fig. 1. Schematic showing the structure of the human calpains. The calpains shown in red are predominantly expressed in speciﬁc tissues or organs; those in black are more widely
expressed. GR, Gly-rich domain; C2, protein kinase C conserved domain 2; MIT, microtubule interacting and transport motif; Zn, zinc-ﬁnger motif; SOL, small optic lobes product
homology domain; IQ, calmodulin (CaM)-interacting motif.
Y. Ono et al. / Biochimie 122 (2016) 169e187 171functions (Table 1). Although all conditions caused by calpain de-
fects called calpainopathies, this review focuses on calpainopathies
caused speciﬁcally by defects in CAPN3 function, among which
Limb-Girdle Muscular Dystrophy (LGMD) type 2A (LGMD2A) was
the ﬁrst human disease found to be caused by a calpain deﬁciency.Fig. 2. CAPN3 missense mutations in LGMD2A patients. So far, 229 distinct missense mutatio
secondary structures shown are for inactive calpain-2 (1KFU).2.2. Discovery of a third, organ-speciﬁc calpain
2.2.1. Early nomenclature
Rat cDNA encoding a third calpain, distinct from both CAPN1
and CAPN2, was found in 1989. The encoded protein was namedns at 189 aars of CAPN3 have been reported in the Leiden Open Variation Database. The
Fig. 3. Representative CAPN3 isoforms generated by alternative splicing of CAPN3/Capn3. See Fig. 1 and Table 1 for abbreviations and detailed structures.
Y. Ono et al. / Biochimie 122 (2016) 169e187172“p94” [44]. At the time, we had no information about the subunits
of a hypothetical active enzyme containing p94 as a catalytic sub-
unit, and we wanted to reserve the name “calpain-3” until the
nature of the enzyme was elucidated. In retrospect, this may not
have been the best decision, since the enzyme still has not been
completely characterized, even to the present day, due to its
extraordinary instability. The name CAPN3, rather than p94, was
recommended for this molecule at the 2013 FASEBmeeting [38,40],
and our review follows the FASEB recommendation. Even apart
from questions of nomenclature, CAPN3 has posed thorny and
perplexing research issues since its discovery.2.2.2. CAPN3 deﬁnition and orthologs
After the discovery of CAPN3, related molecules were cloned in
rapid succession. In 1990, the human gene CAPN3 was determined
to be in chromosome 15 [45]. Human CAPN3was cloned in 1995 [4],
followed by the cloning of parts of the rat and mouse Capn3 genes
in 1996 [46], of chicken cDNA in 1996 [47], and of bovine and ovine
cDNA in 1999 [48]. Since then, nucleotide sequences have been
collecting in gene databases at an astonishing pace, enabling the
identiﬁcation of CAPN3 orthologs in a variety of vertebrates and
making it possible to consider CAPN3 evolution [49,50] (see Figs. 2
and 4). A clear ortholog, however, has not been found in non-
vertebrate organisms [39,40,49e51]. Although the calpain Ha-
CalpM is found in lobsters, primarily in striated muscle [52,53],
this molecule lacks the PEF domain and is thus not an exact CAPN3
ortholog.
CAPN3 has three regions that are not found in CAPN1 or CAPN2.
These regions are at its N-terminus (NS), within the PC2 domain
(IS1), and between the CBSW and PEF domains (IS2) (Fig. 1). All of
unique characteristics of CAPN3 originate from IS1 and/or IS2, and
these regions deﬁne a molecule as CAPN3. The sequence conser-
vation of IS1/2, however, is very low among vertebrate CAPN3s (see
Fig. 5), rendering a CAPN3 deﬁnition by IS1/2 sequences impossible.
At present, it is reasonable to deﬁne a calpain as CAPN3 if it has
more signiﬁcant similarity to human CAPN3 than to human CAPN1
or CAPN2. Although this deﬁnition excludes all calpains in non-vertebrate organisms, some of these calpains may play roles that
are similar to that of CAPN3.
2.2.3. Found ﬁrst in skeletal muscle, and later throughout the body
CAPN3 was ﬁrst identiﬁed as a calpain present in mammalian
skeletal muscle [44]. At the time, Northern blot analysis was not
sensitive enough to detect CAPN3 mRNA in other tissues we
examined. However, improvements in sensitivity and detection
revealed that CAPN3 mRNA is present in most tissues. In mammals,
CAPN3 is expressed far more strongly in skeletal muscles, especially
in the fast (type II) ﬁbers [54], than in other tissues. In the heart,
CAPN3 mRNA has been detected but not its protein [55]. During
human development, CAPN3 appears relatively late compared to
other muscle components, such as connectin/titin (TTN) and sar-
coglycans (SGCs) [56], and the same is true in mice [57,58].
In chickens, CAPN3 is abundantly expressed in the skeletal
muscles, and considerable amounts are also expressed in the brain,
liver, and heart [47,59]. The CAPN3 level decreases seven days after
hatching, while the CAPN1 and CAPN2 levels remain constant,
suggesting that the function of CAPN3 in chickens differs slightly
from that inmammals [60]. The CAPN3 expressionpatterns also vary
somewhat in lower vertebrates [49], indicating that physiological
role of CAPN3 may have changed during evolution.
In myocytes, CAPN3 exists everywheredin the cytosol; at the Z-
line, N2A, and M-line regions; around the sarcoplasmic reticulum
(SR); and so on [7,61e66]. CAPN3 carries at least one potential
nuclear-translocation signal sequence in IS2 [50], although the
nuclear localization of CAPN3 in skeletal muscles has been rarely
observed in vivo (cf. melanoma cells, Section 3.3). This important
issue should be examined further.
3. Defensive role of CAPN3 against disease
Calpains are sometimes categorized as disease-causing en-
zymes, and it is true that calpain activity often exacerbates path-
ological states. However, CAPN3 generally defends the body against
disease, and defects in CAPN3 lead to LGMD2A (for detailed clinical
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3.1. The calpainopathy LGMD2A
3.1.1. La Reunion paradox
In 1995, six years after the discovery of CAPN3, CAPN3 was
identiﬁed as the gene responsible for LGMD2A [4,74e76]. This
landmark report identiﬁed six different CAPN3 mutations in fam-
ilies on La Reunion Island [4]. This was dubbed the “La Reunion
paradox,” because for a rare disease such as LGMD2A, the existence
of plural distinct mutations in one gene in a small geographic re-
gion was considered contradictory [77]. Similar cases have since
been reported [78e80], and this apparent paradox was later
consolidated as a compound heterozygous probability in a
consanguineous population, which is “not so unexpected” [80].
Every pair of individuals and every community has an
“inbreeding coefﬁcient (f)” between 0 and 1, representing the de-
gree of consanguinity (e.g., f ¼ 1 between completely inbred mice,
0.5 between two clones of an individual, and 0.0625 between two
cousins). In actuality, the highest f observed in natural populations
is 0.149, and the f in the La Reunion Island population is presumed
to be much less than this value. The proportion (P) of affected,
compound-heterozygous individuals to homozygous individuals in
a population with f is given by the following formula [80]:
P ¼ (n 1)q(1 f)/[nq(1 f)þf], where n and q are the number and
the frequency of disease alleles, respectively. Assuming f ¼ 0.07,
n ¼ 6, and q ¼ 0.0012 for La Reunion Island (q is calculated from n
and the disease relevance of 4.8  105), P is calculated to be 7%,
which is not statistically signiﬁcant. The values of f and n are
probably less and more, respectively, than those presumed above,
making P higher (e.g., if f ¼ 0.04 and n ¼ 12, then q ¼ 0.00058 and
P ¼ 13%).
However, this phenomenon does not explain why there are so
many CAPN3 alleles; the Leiden Open Variation Database, at www.
dmd.nl, lists 493 so far. CAPN3might be in a mutation-prone locus,
the alleles might have various merits for survival when heterozy-
gous, and/or some homozygotes may produce relatively benign or
late-onset symptoms. However, there is little evidence for any of
these possibilities, and the reasons have yet to be clariﬁed.
3.1.2. Mouse models
There are several mouse models for CAPN3 calpainopathy. These
include CAPN3 knock-out (CAPN3-KO) mice [5,6,81]. There are also
transgenic (Tg) mice expressing inactive CAPN3:C129S
(CAPN3:C129S-Tg, in which C129, one of the active-site triad aars, is
replaced) [82] or a splicing variant (CAPN3:Dex6-Tg and CAPN3:-
Dex15-Tg, in which exons 6 and 15 encoding IS1 and a part of IS2,
respectively, are deleted) [83]. CAPN3:C129S knock-in
(CAPN3:C129S-KI) mice express CAPN3:C129S instead of wild-type
(WT) CAPN3 [7]. The ﬁrst KO mice showed transmission-ratio
distortion, which turned out to be an artifact of the introduced
Pgk1 promoter [81]. All of these mouse models exhibit a myopathy
phenotype with slight differences in severity, from the most benign
to the most severe as follows: CAPN3:C129S-Tg < CAPN3:C129S-
KI < CAPN3-KO < CAPN3:Dex15-Tg < CAPN3:Dex6-Tg. These results
suggest that CAPN3 and its splicing variants have complex functions
in muscle.
3.1.3. Genotype-phenotype correlations
Many LGMD2A pathogenic mutations have been reported along
with their phenotypes, including 229 missense mutations (Fig. 2)
[84e87]. However, it is difﬁcult to establish clear genotypeephe-
notype correlations because of the high variability of symptoms
and severity (see also 4.2.4), even among patients with the same
CAPN3 genotype [84,87e89]. CAPN3 is clearly not the sole factor inthese symptoms [77]. It should also be noted that LGMD2A is
completely recessive: heterozygous humans with an entire CAPN3
deletion have no symptoms, indicating that half-normal levels of
CAPN3 are sufﬁcient to maintain skeletal muscle [85].
3.2. Eosinophilic myositis (EM)
In 2006, CAPN3 mutations were identiﬁed in six unrelated EM
patients [90,91], and other cases have since been identiﬁed
[92e94]. These CAPN3 mutations, which include R49C, R101K,
P102S, T184M, G222R, R490W, R769P, W360*, and truncations in
the PEF domain and in intron 5, have not been linked to speciﬁc EM
characteristics [91]. Since CAPN3 is also expressed in immune cells,
the loss of the CAPN3 protein and its function may cause immu-
nological defects. CAPN14, which is predominantly expressed in
esophagus mucosa, was recently found to be responsible for
eosinophilic esophagitis [33,95] (Table 1). The CAPN14 expression
in esophageal epithelial cells is normally upregulated by
interleukin-13 secreted from immune cells. The induced CAPN14 is
believed to suppress the immune response, although the mecha-
nisms are unknown. A decrease in CAP14 induction due to nucle-
otide polymorphisms would create a risk for esophagitis. Since
CAPN3 and CAPN14 belong to the classical calpains, whose sub-
strate speciﬁcities are considered similar, CAPN3 may play similar
roles in skeletal muscle. However, if CAPN3 mutations perturb
immune responses, LGMD2A patients should have some immu-
nological defects, and this is not the case. Mouse models of CAPN3
calpainopathy should be re-examined for indications of EM.
3.3. Tumors
In 2004, CAPN3 was found to be highly expressed in melanoma
cell lines [96] and to be downregulated by the anti-melanoma ef-
fects of interferon (IFN)-g [97] or -bwithmezerein (an antileukemic
reagent) [98]. However, overexpressing CAPN3 does not promote
growth in these melanoma cell lines, suggesting that CAPN3 is not
causative for melanoma [98]. In fact, CAPN3 is downregulated in
the metastatic melanoma cell line M14, and the inhibition of con-
ventional calpains signiﬁcantly stimulates extra-cellular matrix
invasion [99]. It should be noted that these studies examined
CAPN3 mRNA only, not the protein.
Two CAPN3 products, hMp84 and hMp78 (see Fig. 3), are
expressed in human melanoma cells through the alternative initi-
ation exon 1C [100] with and without exon 6, respectively [101].
These CAPN3 isoforms were upregulated in M665/2/21 melanoma
cells when treated with apoptosis-inducing cisplatin [101]. Both
hMp84 and p78 are unstable in melanoma cells, since the full-
length protein with a presumed autolytic fragment of ca. 62 kDa
was only faintly detected [101]. This 62-kDa fragment was detected
in both nuclei and the cytosol. Intriguingly, these variants were
downregulated in malignant melanocytic lesions compared to
benign nevi in vivo [101]. Conversely, overexpressing hMp84, but
not its inactive mutant hMp84:C42S, in A375 and HT-144 mela-
noma cells stabilized p53 and upregulated reactive oxygen species
production, leading to cell death [102].
In urothelial tumors, CAPN3 was found in a complex with the
E2F3 transcription factor, which plays a crucial role in carcino-
genesis in the human bladder [103]. Accordingly, although CAPN3
is not expressed in normal bovine bladders, CAPN3 has been found
in pathological bovine bladders, where its proteolytic activity was
several times higher than that of calpain-2 [103].
Altogether, CAPN3 plays essential roles in tumor-cell develop-
ment and metastasis. Further studies, however, are required to
elucidate CAPN3 functions in these events and to determine
whether CAPN3 promotes or suppresses tumor growth, whether
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calpains are also involved.
3.4. Diabetes
The relationship between CAPN3 expression and diabetes has
been examined using fat sand rats (Psammomys obesus) as an ani-
mal model of obesity [104]. In these rats, the amount of CAPN3 in
skeletal muscles is negatively correlated with fat mass and the
concentration of circulating glucose, and positively correlated with
carbohydrate oxidation and energy expenditure. On the other hand,
fasting and refeeding do not affect CAPN3 expression in healthy
human skeletal muscles [105]. At present, these are the only reports
examining CAPN3 and diabetes, and this area deserves further
study to evaluate whether CAPN3 is involved in diabetes-related
biological phenomena.
4. Structure and activity
4.1. Structures
4.1.1. Tertiary structure
Three-D structure of CAPN3 has not been solved entirely.
However, its PEF domain is highly similar to that in other PEF
proteins [106]. Unlike other calpains, CAPN3 PEF binds four Ca2þ
ions, to EF1, 2, 3, and 5. In other calpains that have been analyzed,
EF5 is used to form dimers [107], not to bind Ca2þ. Since CAPN3 and
CAPN2 are highly similar (47% identity) except for NS/IS1/IS2, 3D
CAPN3 modeling was performed without these regions [108].
Based on the aar positions of most of the missense mutations that
produce calpainopathies, these mutations are likely to perturb
inter-domain interactions and interfere with the proper CAPN3
conformation [108].
4.1.2. Possible homodimerization
PEF proteins often dimerize with other PEF proteins, whether
identical or distinct. For example, the CAPN1, CAPN2, CAPN13,
CAPNS1 [109e112]; grancalcin [113,114], ALG2 [115], and sorcin
[116] PEFs form homodimers, and the CAPN2-CAPNS1 [117e120] or
CAPN9-CAPNS1 [112] PEFs form heterodimers. Accordingly, CAPN3
PEFs dimerize with each other [106,112,121]. This ﬁnding implies
that full-length CAPN3 may also homodimerize, and the estimated
resulting 3D structure places the two active sites at opposite ends
[106].
However, interaction between full-length CAPN3 molecules has
not yet been reported. Since the dimerization of PEF proteins is
affected by solution conditions, especially the Ca2þ concentration,
full-length CAPN3 may homodimerize only under speciﬁc condi-
tions. Nevertheless, the native quaternary structures of CAPN3 have
yet to be investigated, including interactions of CAPN3 with other
proteins, described below.
4.1.3. A variety of splice variants
Unlike CAPN1 and CAPN2, CAPN3 produces many splicing vari-
ants (Fig. 3, Table 2). The ﬁrst variant, discovered in 1998, was Lp82,
which is predominantly expressed in the rodent lens [122],
particularly in the cytoplasm of the cortical and nuclear ﬁbers
[123]. Lp82 uses exon 1B (also called AX1), which adds an N-ter-
minus that is distinct from that of adult skeletal-muscle type full-
length CAPN3 (p94) and that lacks exons 6, 15, and 16. As a
result, the NS, IS1, and IS2 regions are almost entirely missing from
Lp82.
Other splicing variations have since been reported, including
Lp85 (Lp82 þ IS3) in the lens [124], Rt88 (Lp82 þ IS1) in the retina
[125], and several isoforms expressed in embryonic muscles (p94lacking exons 6, 15, and/or 16) [58]. Since the IS1/2 regions are
responsible for many of unique characteristics of p94, these splice
variants' properties are rather different from those of p94. Lp82 is
stable (unlike p94), and it functions much like the conventional
calpains. Adding IS1, but not NS or IS2, makes Lp82 as unstable as
p94 [123,126]. Intriguingly, the expression patterns of CAPN3 var-
iants in the lens and retina differ among mammalian species [127],
and functional exon 1B only exists in rodents [127,128].
In skeletal muscle, the ratio of CAPN3 variants to p94 decreases
as development proceeds [57], eventually dropping to less than 1%,
whereas the proportion of variants in the heart, brain, lung, and
retina, and other tissues remains at 10e100% [129]. Cattle have a
short CAPN3 isoform that encodes the N-terminal 12.9-kDa peptide
[130]. Taken together with the disease phenotype of CAPN3:Dex6-
and Dex15-Tg mice, CAPN3 splicing variations and expression
changes are likely to play important roles in skeletal-muscle
development.
The CAPN3/Capn3 genes have the initiation exons 1C (AX2), 12B
(AX3), and 14B (AX4) in addition to those functioning in skeletal
muscle (exon 1) and the lens and retina (1B). Exon 1C is driven by a
rather non-speciﬁc promoter, whereas 12B and 14B are predomi-
nantly expressed in the testis and melanoma, respectively [100].
The variant hUp84, which uses exon 1C, is abundant in immune
tissues and in some lymphocytes, and active CAPN3 with exon 1 is
also present in these tissues [131,132]. The presence of these vari-
ants in peripheral blood cells can be used to diagnose LGMD2A
[133].
4.2. Activation
4.2.1. Rapid, exhaustive, and apparently Ca2þ-independent
autolytic activity
The most striking feature of CAPN3 is its (1) extremely rapid, (2)
exhaustive, and (3) apparently Ca2þ-independent autodegradation
activity [65]. This characteristic autolysis was observed in CAPN3
generated in in vitro translation systems [65,134], in a baculovirus-
Sf9 expression system [135], by expression in cultured cells (except
for skeletal-muscle primary cultured cells) [65], and in endogenous
CAPN3 in skeletal-muscle cell extracts [65,135].
The extreme rapidity of CAPN3 autolysis depends on IS1 and IS2
[65]. The exhaustiveness probably involves other protease(s), as well
as ability of CAPN3 to undergo interMOlecular Complementation
(iMOC) (see Section 5.1). Finally, this autolysis, which appears to be
independent from Ca2þ since it is not inhibited by excess EDTA, is
actually activated by Naþ [136] (see Section 4.2.2). These fascinating
properties are unique among known calpains.
On the other hand, in the presence of physiological intracellular
Naþ concentrations ([Naþ]i), CAPN3 is activated by physiological
[Ca2þ]i; these levels are much lower than those known to activate
other classical calpains, including CAPN3:Dex6/15/16 (p94D)
[137e139]. Conventional calpains require salt bridges between the
PC2 and CBSW domains and a linker between the CBSW and PEF
domains for their activation and stability [117,118]. Mutations dis-
rupting these interactions lower the [Ca2þ] required to activate
calpain-2 [140,141]. In CAPN3, the aars corresponding to these
positions are different, which may explain low Ca2þ requirement of
CAPN3 for activation. In addition, stability and Ca2þ sensitivity of
calpain-2 are also regulated by N region of CAPN2, which interacts
with the PEF domain [141e143], and this region is markedly
different in CAPN3. This difference in N regions may also contribute
to lower Kd of CAPN3 for Ca2þ [141].
4.2.2. Naþ-dependency
CAPN3 is activated by Naþ in vitro, although the physiological
relevance of this regulation is still elusive. The [Naþ] and [Ca2þ]
Table 2
Representative mammalian CAPN3/Capn3 transcripts.
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absence of the other ion. When both ions are present, however,
CAPN3 is activated additively by both ions; e.g., when [Ca2þ]i is 0.1,
1, or 10 mM, [Naþ]i of 15, 8, or 2 mM half-maximally activates
CAPN3, respectively [136]. In other words, CAPN3 is activated by ca.
physiological [Naþ]i and [Ca2þ]i. CAPN3 is the ﬁrst (and so far, the
only) Naþ-dependent intracellular enzyme.
Mutations in the potential Ca2þ-Binding Site(s) in PC1 (CBS-1),
but not PC2 (CBS-2), compromise Naþ-dependency of CAPN3,
indicating that CAPN3 CBS-1 may have evolved to bind Naþ. De-
leting both IS1 and IS2 completely abolishes Naþ-dependent acti-
vation of CAPN3 without changing its Ca2þ-dependent activity
[136]. Thus, Naþ-dependent activity of CAPN3 requires cooperation
among CBS-1, IS1, and IS2.
Potential substrates of Naþ-activated CAPN3 include tropomy-
osin, LIM-domain-binding protein 3, and a-actinin-3, all of which
are in the Z-line [136]. CAPN3 localizes to the Z-line by binding a-
actinin-2 (ACTN2, sarcomeric-a-actinin) [57], indicating that Naþ
dependency of CAPN3 may play a role in its functions in the Z-line.
Autolytic activity of CAPN3 is suppressed in skeletal muscle cells
by its binding to TTN or PLEIAD (see Section 6.2.1). However,
immediately after homogenizing tissues, CAPN3 rapidly autode-
grades in solutions containing Naþ, such as buffered saline. This
was not recognized until recently, and early studies of tissuesamples extracted using saline may need to be performed again
using buffers lacking Naþ. It is important to exclude Naþ from any
buffer when diagnosing LGMD2A [144].
4.2.3. Autolysis and activation
The activation of conventional calpains occurs almost concom-
itantlywith their N-terminal autolysis [145e147], which is reported
to precede caseinolytic activity of calpain [148] and to parallel the
calpains' autodegradation and inactivation [149]. By deﬁnition,
calpain activity must exist during autolysis, but further “activation”
may be required for calpain to proteolyze substrates. This point can
be clariﬁed by using more speciﬁc deﬁnitions of activation.
The ﬁrst step of calpain activation is its intraMolecular (iM)-
activation upon binding Ca2þ (or, in the case of CAPN3, Naþ also).
This iM-activation enables calpains to hydrolyze peptide bonds;
however, steric hindrance, with the N region for example, prevents
calpains from proteolyzing substrates. A second step of calpain
activation is that of extraMolecular (eM)-activation, which allows
calpains to contact substrates. Whether autolysis is required for the
eM-activation of conventional calpains is still controversial.
Due to strong autolytic activity of CAPN3, the full-length WT
protein can hardly be manipulated in vitro. Therefore, most
biochemical CAPN3 studies have used mutants or partial CAPN3
proteins. A study using only the CAPN3 CysPc showed that CAPN3
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that its eM-activation requires IS1 nicking [150e152]. IS1 is pro-
teolyzed intramolecularly; in the presence of IS1, even small-Mr
calpain inhibitors like E64 cannot prevent CAPN3 autolysis. These
ﬁndings explain several of unique properties of full-length CAPN3,
but not its rapid autolysis or dependency on Naþ; these charac-
teristics involve the IS2 region. Ca2þ-dependence of full-length
CAPN3 has also been demonstrated in a baculovirus-expression
system [153] and in skeletal-muscle skinned ﬁbers [154].
The autolytic sites in IS1 are located after Y274, N296, and Y322
[155]; CAPN3:Y274A loses both its autolytic and proteolytic activ-
ities [156]. These ﬁndings support the idea that IS1 proteolysis is
required for full-length CAPN3 eM-activation. Moreover, autolysis
in IS1 does not immediately cause the dissociation of CAPN3 frag-
ments; it is the subsequent proteolysis in IS2 that ﬁnally inactivates
CAPN3 [126,157]. The TTN N2A region suppresses IS2 proteolysis
and the subsequent dissociation of CAPN3 fragments.
In some case, two CAPN3 fragments that are cleaved only in IS1
dissociate, thereby inactivating CAPN3. These fragments can
become active again by the CAPN3-speciﬁcmechanism called iMOC
(see Section 5.1). Since physiological [Naþ]i and [Ca2þ]i are enough
for CAPN3 activation, CAPN3 is probably already iM-activated in the
cell, requiring only IS1 nicking for its eM-activation (Fig. 4).
4.2.4. Mutations in calpainopathy and CAPN3 activity
Although mutations that inactivate CAPN3 cause calpainopathy,
not all calpainopathy-mutant CAPN3s lose their proteolytic activity
[158]. There are ﬁve defective CAPN3 states: (1) completely inactive
(loss of iM-activation ability), (2), inactive as to substrate proteol-
ysis by loss of eM-activation ability, (3) inactive due to overly rapid
autolytic activity or (4) improper substrate recognition, and (5)
defective in non-proteolytic functions but with proteolytic
activity (5).
4.2.4.1. Case (1): inactive mutations. Mutations at evolutionarily
conserved aars in the CysPc domain are highly likely to inactivate
CAPN3. This inactivation stabilizes CAPN3 when ectopically
expressed in cultured cells [159]. However, this is not necessarilyFig. 4. A scheme of activity regulation of CAPN3. Translated full-length CAPN3 (FL-CAPN3)
nicked (but not dissociated) FL-CAPN3 (nFL-CAPN3) (2). Since nFL-CAPN3 is eM-activated
components (N31K and C58K) dissociate from each other (4), and/or degradative reaction pre
N31K and C58K reconstitute the activity by iMOC1 and/or iMOC2 (5), which accelerates au
functions distinctly from FL/nFL-CAPN3 under alternative regulation (7), and/or is ultimatetrue in vivo (e.g., inactive CAPN3:V354G is lost in vivo [87]). This
suggests the existence of one or more CAPN3-mutant degrading
proteases that are present in skeletal muscles but not in non-
muscle cells. This is also the case with some mutations outside of
CysPc. D607 in IS2 is conserved from ﬁsh to humans (see Fig. 7), and
a D607A mutation attenuates the CAPN3 activity [160]. Further-
more, screening by p94-trapping, which uses a yeast two-hybrid
system to detect activity-attenuated CAPN3 mutants, identiﬁed
I603T, F604 L/S, V605A, and D607N [160]. Notably, a neighboring
mutation, S606L, causes LGMD2A [161]. Taken together, the short,
evolutionarily conserved stretch around D607 in IS2 is essential for
proteolytic activity of CAPN3.
4.2.4.2. Case (2): mutations that disable eM-activation. Some IS1
mutations, including Y274A, cause defective IS1 nicking, which
disables eM-activation [156]. There is an a-helix in the middle of
IS1 that is disrupted by L286P [152]. Interestingly, the CysPc-only
CAPN3:L286P is spontaneously activated during the puriﬁcation
process. This type of CAPN3 mutant may be iM- and eM-activated
simultaneously, resulting in self-destruction, as described in
case (3).
4.2.4.3. Case (3): mutations that accelerate autolysis. If rapid auto-
lytic activity of CAPN3 is accelerated even further, the CAPN3 pro-
tein is lost before it can accomplish its function. This is the casewith
some mutations in the PEF domain, including S744G and R769Q
[159]. Indeed, compared toWT, autolysis is accelerated in calpain-2
with mutations corresponding to those causing LGMD2A: T344M
(T417M of CAPN3), D346E (D419E), D362K (E435K), R417W
(R490W), and G423R (G496R) [162].
Studies using CAPN3 KO mice with transgenic expression of
CAPN3 or its mutants showed that R448H and D705G proteolyzed
muscle extracts faster than WT CAPN3, probably due to their
inability to bind TTN [163]. This experimental system allows any
CAPN3 mutant to be expressed in vivo in place of WT CAPN3.
Moreover, in skeletal muscle extracts, CAPN3 showed slowed
autolytic activity, and this feature might be useful for a CAPN3
autolytic assay.is iM-activated by physiological [Naþ]i and [Ca2þ]i (1), and autolyzes in IS1, producing
and metastable, it functions as a protease (3). Then, nFL-CAPN3 is inactivated as its
dominates through autolysis in IS2 and other sites with the aid of other protease(s) (40).
tolysis of FL-CAPN3 (6). Reconstituted CAPN3 by iMOC1 (iMOC-CAPN3) localizes and
ly inactivated by further autolysis (70).
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In conventional calpains, CBSWand PEF are important for substrate
recognition. CBSW interacts with substrate aars at the P3 and
P5eP10 positions [119,120,164], and PEF is thought to assist in
recognizing CaM-binding proteins as substrates [165]. Therefore,
mutations may disrupt the conformation of these domains,
compromising proper substrate recognition of CAPN3. For example,
R490W and R572Q show reduced, Ca2þ-dependent autolysis but
can barely proteolyze calpastatin or CAPN3:C129S, which are good
substrates for WT CAPN3 [159].
4.2.4.5. Case (5): mutations that interfere with non-proteolytic
functions. The phenotype of CAPN3:C129S-KI mice is between
that of WT and CAPN3-KO mice [7,64], leading to the recognition of
two independent CAPN3 functions: proteolytic and non-
proteolytic. C129S has no proteolytic activity, but its non-
proteolytic function is intact. Some mutations in regions that are
not directly involved in proteolytic function (cases 1e4) may
compromise only the non-proteolytic function, leaving the pro-
teolytic function intact. This may be the case with A702V, which
was found in a homozygous patient that had normal CAPN3 protein
levels and activity [158].
4.3. Molecular evolution
As mentioned above, clear CAPN3 orthologs have been found
only in vertebrates (Fig. 5). Notably, teleosts (bony ﬁsh) have two
paralogous genes as orthologs for most mammalian genes,
including calpains, due to genome duplication in the teleost
ancestor, and evolutionary CAPN3 traits have been glimpsed in
these ﬁsh [166]. Interestingly, the two CAPN3 zebraﬁsh genes show
distinct expression patterns: during early development, Capn3a
expression begins in the lens and expands into the brain between
the eyes, while Capn3b expression is enriched in the digestive or-
gans and in the head region [167].
Capn3a and Capn3b also have contrasting structural features. A
possible nuclear localization signal is detected in the IS2 region of
CAPN3B but not CAPN3A. On the other hand, the Capn3a genomic
environment mimics that of human CAPN3, being located at the 30
region of GANC [100] (Fig. 5). Such trends are conserved among
Capn3s in other teleosts. So far, it has been difﬁcult to identify IS1 inTetrapod
Lobe-finned fish
Ray-finned fish
Jawless fish
Jawed fish
Vertebrate
Teleost
TGD
Human, Mouse, 
Chicken, Turtle
Coelacanth
Spotted gar
Medaka*, Platyfish,
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Fig. 5. Summary of CAPN3 orthologs. CAPN3s from different branches are categorized ac
phylogenetic tree is arbitrary. Gray indicates that the annotated sequence does not align perf
exons 15 and 16, respectively, in humans. **No canonical nuclear localization signal has bee
genes encoding GANC and CAPN3 are found in different chromosomes. TGD, teleost genomteleost CAPN3; the IS1 in tetrapod CAPN3 may be missing or
composed differently in teleosts (Fig. 6). Thus, teleost Capn3s may
represent a vivid example of sub- and/or neo-functionalization
during gene evolution, in which CAPN3A and CAPN3B partitioned
the functions of a single ancestral CAPN3 and/or acquired new
functions for one or both.
Another signiﬁcant feature of CAPN3 gene evolution is that
CAPN3 has the most conserved orthologs among vertebrate clas-
sical calpainsdmore than either CAPN1 or CAPN2 [49] (Table 3).
This is astonishing, considering that Capn2 disruption causes em-
bryonic lethality [2,3], while Capn3 results in muscular dystrophy
[5,6]. This ﬁnding suggests that vertebrates are essentially insepa-
rable from their skeletal muscles, which constitute and maintain
the whole body shape, and that CAPN3 is essentially involved in
these functions. Alternatively, ancestral CAPN3 might have had
functions so pivotal to cell survivaldthe regulation of cell cycles, for
instance (see Section 6.3)das to warrant the conservation of
CAPN3 among vertebrates independently of its expression pattern.
Further research will hopefully uncover novel CAPN3 functions.
5. Unique features
Although extreme instability and rapid autodegradation of
CAPN3 is one of its most startling features, it has several other
unusual characteristics. Although the physiological signiﬁcance of
some of these properties has yet to be established, they certainly
make CAPN3 an enigmatic yet attractive research subject.
5.1. Re-activation after inactivation
The amazing rapidity of CAPN3 autodegradation is thought to
regulate its activity. A recent study demonstrated that de novo iMOC
between the two autolytic fragments of CAPN3 reconstitutes an
active core protease domain [168] (see Fig. 4). Unlike the sustained
interaction that occurs between autolytic fragments in the course
of autolysis, iMOC enables the mutual compensation of two
different CAPN3 mutant molecules if the combination is appro-
priate. It is currently hypothesized that iMOC may rescue a fraction
of CAPN3 protease function in some cases of LGMD2A caused by
distinct missense mutations in both CAPN3 alleles, and this process
may alleviate symptoms [169].N/A
N/A
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e duplication. For sequence alignment, see Ref. [11].
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IMSKALERGSLMGCSIDDTMGITPGV-PAPNALGTLIDRMISQTEADKSKPGEPPTGCTLTF---STHSLVPVRFETRTVTGLVKGHA 325
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Fig. 6. Sequences found in the IS1 region of CAPN3 from species other than tetrapods. The arrow indicates one of the active-site aars, H334, in humans. In tetrapod CAPN3s, IS1 is
encoded, in-frame, by a single exon. *, **: the ﬁrst (white arrowhead) and the last (black arrowhead) aars, respectively, are not in-frame. For full sequence alignment, see Ref. [11].
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few viruses [170], and in no other proteases so far. Uncovering the
molecular mechanisms and physiological relevance of CAPN3 iMOC
and its physiological relevance should be an interesting avenue of
research.5.2. Phosphorylation
Two phosphorylated aars have been found in human CAPN3, at
S629 and S636 in IS2 (Fig. 7); the former is the major site [171]. The
autolytic CAPN3 activity is slightly attenuated by the defective
phosphorylation of S629 but not S636, suggesting that the autolysis
is regulated in part through S629 phosphorylation [171]. Phos-
phorylated CAPN3 (P-CAPN3) is enriched in myoﬁbrils rather than
in the cytoplasm [163,171]. As CAPN3 directly binds TTN and ACTN2
[57,62], it is possible that CAPN3 is selectively phosphorylated in
myoﬁbrils, and this property may be related to TTN-based me-
chano-transduction signaling.
Phosphorylation may also increase afﬁnity of CAPN3 for
myoﬁbrils, causing CAPN3 to accumulate in myoﬁbrils (Fig. 8).
We found that the amounts of both CAPN3 and P-CAPN3 are
reduced in LGMD2A muscle tissues [171,172]. In contrast, WTTable 3
Sequence conservation of CAPN3 vs. CAPN1 among vertebrates. The upper and lower valCAPN3-Tg mice show almost no phenotype [83,173], suggesting
that excess CAPN3 may be absorbed by myoﬁbrils via increased
phosphorylation. Intriguingly, S629 is well conserved among
eutheria, with the exception of a subset of small rodents and
bats, in which S629 is replaced by G. Large eutheria may take
advantage of P-CAPN3, stocking an abundance in skeletal mus-
cles to protect and maintain the muscles and their functions.
Further studies are needed to reveal P-CAPN3 role in normal as
well as pathogenic (e.g., LGMD2A) and physiologically stressed
(e.g., exercised) muscles.5.3. Non-proteolytic function
Non-proteolytic functions of CAPN3 are independent of its
proteolytic function. This idea emerged from data comparing
CAPN3-KO and -KI mice with WT mice [64]. CAPN3 binding to
Aldolase A (ALDOA) is essential to localize ALDOA to the triads,
where the complex interacts with the ryanodine receptor (RyR) in
the SR [174]. Indeed, IS2 region of CAPN3 interacts with RyR, sarco/
endoplasmic reticulum Ca2þ-ATPase, calsequestrin-1 (CSQ1), and
triadine, locating proximally to the SR [64]. Notably, CAPN3 does
not proteolyze thesemolecules in vitro. Furthermore, myotubes andues indicate the identity and similarity of aa sequences, respectively.
PCAPN3
CAPN3
P CAPN3 P CAPN3
P CAPN3CAPN3
CAPN3
kinase
kinase
phosphatase
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Fig. 8. Possible mechanisms for anchoring P-CAPN3 to the myoﬁbrils. These mechanisms postulate the existence of an as-yet unidentiﬁed CAPN3-phosphorylating kinase, either in
the cytosol (A) or myoﬁbril-bound (B). In (A), P-CAPN3 is recruited to the myoﬁbrils by an increased afﬁnity for myoﬁbrils. In (B), recruited CAPN3 is phosphorylated by myoﬁbril-
bound kinase, which may or may not increase the afﬁnity of the molecule for the myoﬁbrils. In either case, dissociated P-CAPN3 is rapidly dephosphorylated by phosphatases in the
cytosol, increasing the accumulation of P-CAPN3 in the myoﬁbril fraction.
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Fig. 7. Conserved sequences of IS2 region found in CAPN3. The sequences correspond to 601e638 aars of human CAPN3. The arrows indicate two phosphorylation sites found in
human (see Section 5.2). For full sequence alignment, see Ref. [11].
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caffeine (RyR agonist) and to Ca2þ release from the SR, respectively,
compared toWT responses [174,175]. In addition, disrupting CAPN3
does not affect Ca2þ uptake into the SR [174].
In CAPN3:C129S-KI mice, the RyR and ALDOA localization and
Ca2þ inﬂux/efﬂux are unaffected [64]. These observations indicate
that CAPN3 has a non-proteolytic functiondthat is, a structural
property that is responsible for regulating SR Ca2þ release. This dual
character of CAPN3 may account for the wide range of LGMD2A
symptoms, at least in part.5.4. Dynamic translocations in skeletal muscle cells
TTN, which was identiﬁed as the ﬁrst known CAPN3 binding
partner in 1995 [62,176], is an essential regulator of CAPN3. TTN is
the largest single polypeptide, spanning half a sarcomeredthat is,
the distance between the Z- and M-lines, which correspond to N
and C termini of TTN. TTN functions as a molecular spring, retaining
the thick ﬁlaments at the sarcomere center through an elastic
property of its I-band region, which is composed of a series of
immunoglobulin (IG) domains [177e179].
CAPN3 binds to N2A and M-line regions of TTN [62,180],
where CAPN3 is proposed to play a role in TTN-based mecha-
nosensory transduction pathways. In stretched sarcomeres,
CAPN3 accumulates at the N2A region, where a protein complex
is formed in response to mechanical stimulation. The TTN I-band
region extends, spring-like, as sarcomeres stretch [181,182], and
thus serves as an ideal “scale” to sense sarcomere extension/contraction, in which a number of molecules cooperate
[183e185].
CAPN3 also locates to the Z-line [57,62]. Intriguingly, CAPN3
alters its position depending on sarcomere length: as the sarcomere
extends, CAPN3 becomes less abundant at the M-lines and more
abundant at the N2A regions [57]. This is probably because the
extension of the TTN I-band exposes CAPN3-binding sites in the
N2A regions, while this area is hidden in contracted sarcomeres by
TTN tangled IGs. Furthermore, the CAPN3 accumulation at N2A
regions is facilitated by protease activity of CAPN3 [7,57]. In other
words, inactive CAPN3 cannot rapidly access the TTN N2A regions
in extended sarcomeres, and this inability may be a contributing
factor in LGMD2A.
As a scaffold to form a protein complex for mechanical signal
transduction [182], the TTN N2A region binds muscle ankyrin
repeat domain protein 2 (ANKRD2, also called MARP2 or ARPP)
[186]. ANKRD2 participates in stress-response pathways and is
upregulated after exercise [187,188]. Insufﬁcient ANKRD2
recruitment is observed in exercised CAPN3:C129S-KI mice,
indicating that protease activity of CAPN3 is necessary for this
mechanosensory transduction [7]. For this physical stress
response, CAPN3 protease activity is required during exercise
rather than after. In addition, CAPN3 activation has been detected
in muscles up to six days after exercise [7,189e191], suggesting
that protease activity of CAPN3 has different roles. In other
words, while CAPN3 activation during and immediately after
exercise triggers mechanosensory transduction, CAPN3 autolysis
after exercise suggests functions such as sarcomere remodeling
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CAPN3 autolysis in skeletal muscle cells in situ cannot be
detected by immunoblotting. Thus, innovative techniques are
required for probing CAPN3 activity in situ to clarify its functions
during and after exercise.6. Molecules that interact with CAPN3
6.1. Molecules responsible for muscular dystrophies
6.1.1. TTN
6.1.1.1. Muscular dystrophy with myositis (mdm). As mentioned
above, TTN serves as a large-scale CAPN3 reservoir. TTN N2A region
has at least three CAPN3-binding sites [186], and binding at these
sites suppresses rapid autolysis of CAPN3 [157]. A severe muscular
dystrophy phenotype in mdm mice was ﬁrst described in 1985
[193,194]. Ttn became a causative candidate in 1993 [195], and the
Ttn small deletion (83 aars) responsible for themdm phenotypewas
identiﬁed in 2002 [194].
The relationship between CAPN3 and mdm is still elusive. A
secondary reduction of CAPN3 in mdm mice was observed in some
cases [196,197] but not in another [198]; this discrepancy may be
due to differences in the developmental stage of the mdm mice or
the sample-preparation methods. The phenotype ofmdmmice was
unaffected by Capn3 KO, but was exacerbated by transgenic CAPN3
expression [197]. These ﬁndings suggest that CAPN3 may be per-
turbed by the mdm mutation, which is not a primary cause of the
mdm phenotype.
6.1.1.2. Tibial muscular dystrophy (TMD) and M-line TTN proteolysis.
TMD is an autosomal dominant late-onset distal myopathy that was
identiﬁed in 1993 [199]. Since it was mapped to chromosome 2q31,
TTN became a candidate causative gene, as with mdm [196,200].
Finally, several mutations in last two exons of TTN (Mex5 and 6), in
which a few aars in the TTN C-terminal region were changed,
identiﬁed as being responsible for TMD, for LGMD2J (when ho-
mozygous), for hereditary myopathy with early respiratory failure,
and for early-onset myopathy with fatal cardiomyopathy
[201e204].
The ﬁrst identiﬁed mutation (FINmaj) changed EVTW to VKEK
(Fig. 9) [201]. Hetero- (HE) and homozygotes (HO) of the FINmaj
knock-in mouse model showed increased embryonic lethality.
Once born, however, these mice appeared to grow normally
and have a lifespan similar to that of WT mice [205]. HE mice,Fig. 9. TTN C-terminal mutations found in TMD, and cleavage sites by calpains. A structure ba
Red arrows indicate the C termini of sites cleaved by both CAPN3 and the conventional calpa
that is probably cleaved by endogenous conventional calpains; the cleavage is suppressed by
physiologically detected under a static condition [16]. Blue vertical lines indicate TMD mutwhich expressed mutant and WT TTN at a ratio of ca. 1:1, showed a
skeletal-muscle dystrophic phenotype from 9 months of age,
whereas the heart was normal. HO mice exhibited a more severe
phenotype with dilated cardiomyopathy. Surprisingly, even though
FINmaj changed only four aars, the mutant TTN lost its last ﬁve C-
terminal IGs (ca. 84-kDa around M6 to M10, Fig. 9) [16].
The FINmaj mutation causes a pathological cleavage of TTN in
M10 and at somewhere around M6 (Fig. 9). FINmaj and some other
mutations are located in the middle of the M10 b-strand or a-helix
[16,206], disrupting an otherwise rather rigid IG conformation
[207] and rendering M10 susceptible to cleavage. This cleavage is
carried out by both CAPN3 and calpain-2 [16], which are reported to
share several other substrate cleavage sites [186,208]. Although this
cleavage has not been conﬁrmed in vivo, the loss of the 84-kDa
extreme C-terminal region is probably caused by further cleav-
ages of TTN aroundM6 (Fig. 9), carried out by CAPN3, calpain-2, and
possibly other protease(s). Although these cleavages were not
reduced in CAPN3 KO muscle, the other protease(s) involved in
these pathological cleavages in vivo have yet to be identiﬁed.
TTN M10 binds the 800-kDa IG-repetitive protein, obscurin
(OBSCN), and its smaller paralog, obscurin-like 1 (OBSL1,
130e230 kDa) [209e212]. These proteins, together with the
myosin-interacting M-line proteins called myomesins (MYOM1-3),
form an elastic web in the M-line [213,214]. Thus, pathological
cleavage in M10 very likely disrupts the integrity of the M-line
structure, including the dissociation of OBSCN/OBSL1 from TTN
[211,212], which would make the TTN M-line susceptible to pro-
teolysis. Myospryn (also called CMYA5) binds to both CAPN3 and
the C-terminal region of TTN [215]. Myospryn appears to be pro-
teolyzed by co-expressed CAPN3 in cultured cells, and its binding to
CAPN3 slightly suppresses CAPN3 autolysis [215]. Thus, this mole-
cule may also be involved in the M-line instability caused by M10
proteolysis.
6.1.2. Dysferlin and LGMD2B
Dysferlin (DYSF) is a multi C2-containing protein involved in
membrane repair. This protein is responsible for LGMD2B, Miyoshi
myopathy, and distal myopathy [216]. Secondary CAPN3 reduction
has been reported in LGMD2B, as with TMD, suggesting a link be-
tween CAPN3 and DYSF [217]. Biochemical studies show that
CAPN3 directly interacts with DYSF [218] and with the DYSF-
interacting protein AHNAK (also called desmoyokin) [219].
AHNAK is proteolyzed by CAPN3, suggesting that CAPN3 regulates
the DYSF complex [219], although CAPN3 is not directly involved in
membrane repair [220,221]. Since LGMD2A and 2B account for thesed on the sequence of N2A-type TTN (NP_596869; 33,423 aars, ca. 3.7 MDa, 1e1.5 mm).
ins; black arrows indicate those cleaved by calpain-2. The dotted arrow indicates a site
deleting mdm. The 44-kDa proteolytic fragment cleaved at the C-terminus of E33,017 is
ations.
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should be examined further.
6.1.3. RBBOX1, a Capn3 splicing regulator
Facioscapulohumeral muscular dystrophy (FSHD) is an auto-
somal dominant disorder characterized by facial and shoulder-
girdle muscle weakness [222]. A deletion at the 4q35 region has
been found in FSHD patients. This deletion upregulates several
genes in this region, including FRG1 (FSHD region gene 1), which
encodes a possible RNA-processing protein [223]. Mice over-
expressing FRG1 have an FSHD-like phenotype [224] with a
downregulation of RBBOX1, an alternative splicing regulator;
knocking down RBBOX1 decreases full-length CAPN3 and increases
the Dex6 CAPN3 variants [225]. As mentioned above, CAPN3:Dex6-
Tg mice have a severe phenotype, indicating that the deﬁciencies
found in FSHD can likely be ascribed, at least in part, to aberrant
CAPN3 splicing. Of note, some FSHD-like patients also carry CAPN3
mutations [226].
6.2. Suppressor and activator
6.2.1. Pursuit of a CAPN3 suppressor in the cytosol
Interaction proteomics is a powerful, highly sensitive method
for capturing protein networks. Using CAPN3 as a bait, this meth-
odology identiﬁed a PLatform Element for Inhibition of Autolytic
Degradation of CAPN3 (PLEIAD) [208]; this molecule was previ-
ously known as C5orf25 and as SIMC1, a poly-SUMO interacting
protein [227]. Protein co-expression experiments demonstrated
that PLEIAD moderates both protease activity and autolysis of
CAPN3, as in the case of N2A fragment of TTN. Cellular localization
of PLEIAD is dominantly cytosolic, with occasional sarcomeric I-
band localization. Therefore, PLEIAD is regarded as a candidate
regulator of CAPN3 residing outside of the sarcomere structure.
C-terminal region of PLEIAD, which suppresses CAPN3 activity,
is well conserved in vertebrates. As with CAPN3, no homologous
sequence for PLEIAD has yet been identiﬁed in invertebrates.
Intriguingly, N-terminal region of PLEIAD also interacts with the
transcriptional regulator, C-Terminal Binding Protein 1 (CTBP1),
which is a good substrate for calpains including CAPN3 [208].
Although this ﬁnding implies that PLEIAD is a scaffold for prote-
olysis by CAPN3, further studies of physiological functions of
PLEIAD are necessary to conﬁrm this.
6.2.2. CaM as an activator of CAPN3
Recently, CaM was shown to promote CAPN3 activation [228].
Crude muscle extracts of CAPN3-KO mice that Tg-overexpressed
CAPN3 WT or C129S were used for CAPN3 assays as described
above. In this assay, ectopically added CaM facilitated the autolysis
of CAPN3 as well as the proteolysis of TTN by CAPN3 [228], sug-
gesting CaM as the ﬁrst positive regulator of CAPN3 to be
discovered.
6.3. Possible involvement of CAPN3 in cell-cycle regulation
In MCF7 cells (derived from human breast cancer) and HepG2
cells (derived from human hepatoblastoma), the degradation of
p53 in the nucleus is mediated by CAPN3 and Digestive organ
Expansion Factor (DEF, also called DIEXF and C1orf107) [167]. The
p53 molecule is a well-known regulator of a variety of cellular
functions; its turnover is mediated mainly by MDM1 via the
ubiquitin (Ub)-proteasome system, and also by Ub-independent
proteasome degradation and by calpains [229e232]. DEF is a
nucleolar protein involved in rRNA processing and p53 regulation
[233,234]. CAPN3 directly binds to DEF and negatively regulates
p53, downregulating p53-mediated gene expression [167].Accordingly, knocking down CAPN3 in HepG2 cells increases the
proportion of G1-arrested cells.
This increase in G1-arrested cells is conserved in zebraﬁsh,
which has two CAPN3 genes, Capn3a and Capn3b, as described
above. CAPN3B, but not CAPN3A, is involved in downregulation of
p53 in a manner depending on active site C120 of CAPN3B [167],
although which CAPN3 isoform(s) are involved is unknown at
present. We also do not know whether these observations are
exceptional and speciﬁc to restricted conditions, or if CAPN3 pro-
teolytic activity is generally involved regulating p53 or cell cycles.
So far, systemic defects related to dysregulated cell cycles have not
been reported in calpainopathy patients or Capn3 KO mice. How-
ever, CAPN3 variants lacking IS1/2, such as hUp84 and hMp84, are
very likely used for these functions, which can be taken over by
other classical calpains when CAPN3 is defective. In other words,
cell-cycle control may be one of the most important functions for
classical calpains, at least in vertebrates.
The transcription of rRNA and construction of ribosomes take
place in the nucleolus. Thus, nucleolar localization of CAPN3 im-
plies that it has functions related to RNA metabolism. During our
PLEIAD screening, we identiﬁed several RNA-binding proteins
involved in stress granules ([208] and unpublished results).
Together with the fact that translational machinery components
are potential CAPN3 substrates (see Section 6.4), the recruitment of
CAPN3 to the nucleolus by DEF may be physiologically relevant. In
addition, the conventional calpains proteolyze heterogeneous nu-
clear ribonucleoprotein (RNP) K [235] and SMN protein, both of
which are involved in small nuclear RNP biogenesis [236,237]. One
of the PEF proteins, ALG-2, is associated with the P-body, another
location where RNA metabolism takes place [238]. These points
merit further investigation.
No clear CAPN3 orthologs have been identiﬁed in non-
vertebrates. In these organisms, CAPN3 functions may be carried
out by other calpains. For example, Saccharomyces cerevisiae has a
single calpain gene, RIM13 (previously called CPL1) [239,240],
which may act with Utp25, a yeast DEF ortholog that mediates
rRNA processing. In this context, the lack of any calpain in Schizo-
saccharomycetes [39] is mysterious, since it has Utp25 orthologs.
Alternatively, the calpains' p53-degrading function may have
been acquired during the evolution from invertebrates to verte-
brates. The N-terminal 100e200 aar regions of DEF/Utp25 are not
conserved between vertebrates and invertebrates, whereas human
and zebraﬁsh share 53% identical aars in these sequences. In any
case, the involvement of CAPN3 and other calpains in the cell cycle
should be investigated in the near future.
6.4. Substrates
CAPN3 WT, but not C129S, has strong autolytic and proteolytic
activity when expressed in cultured cells, without any additional
activation process [65]. Thus, it is easy to test whether CAPN3
proteolyzes particular proteins in cultured cells. These types of
studies have identiﬁed various in vitro substrates, including ALDOA
[174], ANKRD23/CARP/MARP1 [241], C/EBPa [242], ﬁlamin C
[156,243], IkB [244], ezrin, talin, vinexin [156], conventional cal-
pains, calpastatin [139], b-oxidation enzyme (VLCAD) [245], TTN
N2A, M- and Z-line regions [16,156,186], PIAS [246], RyR [247],
AHNAK [219], spectrin [159,248], MyoD [249], and CTBP1 [208].
Proteomic studies have identiﬁed additional substrate candi-
dates, including eukaryotic translation initiation and elongation
factors [134], glyceraldehyde-3-phosphate dehydrogenase [134,250],
PDZ and LIM domain 1 (PDLIM1) [251], troponin T, and CSQ1 [136].
Most of these candidates have yet to be veriﬁed for physiological
proteolysis by CAPN3. However, several molecules identiﬁed in in-
dependent studies and involved in the same biological context are
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ponents andmolecules involved inprotein translation and glycolysis.
There are too few known cleavage site sequences to analyze
substrate speciﬁcity of CAPN3 at present. Considering that CAPN1,
CAPN2, and CAPN3 are highly similar, speciﬁcity of CAPN3 should
be similar to those of calpain-1 and -2, which are almost identical
[164,252e254]. Using several CAPN3 cleavable fragment se-
quences, a possible CAPN3-recognizing motif in the vicinity of
cleavage sites was proposed [246]. However, since the cleavage
sites of these fragments have not been identiﬁed, the distances
between these motifs and the cleavage sites are unclear. There is no
such motif around the cleavage sites identiﬁed in calpastatin [139],
CTBP1 [208], PDLIM1 [251], or TTN N2A [186].
The substrate speciﬁcity of conventional calpains is neither
explicit nor ambiguous. Although a clear rule has not been found,
cleavage sites can be predicted fairly successfully [164,255e257].
Cleavage studies unexpectedly revealed that calpains proteolyze
many sites in vitro if the peptides are unstructured. In other words,
the limited proteolytic action of calpains in vivo is mostly deﬁned by
the native structures of the substrates. The same can be expected
for CAPN3, and researchers must be conscious of 3D structures
when evaluating substrate proteolysis of CAPN3 and physiological
signiﬁcance.
7. Perspectives and conclusions
Just over 26 years ago, we discovered a calpain homolog. Some
may have considered it just another calpain; others may have
thought it was an artifact or a pseudogene product, since no protein
was found at the time. At that time, we tried to purify CAPN3 from
muscles, but without success. When it was discovered that Naþ
caused CAPN3 to autodegrade, we tried a different puriﬁcation
method: we replaced all of the Na salts used for column chroma-
tographies with Cs salts (so expensive!) and used 5 L of rabbit
skeletal-muscle homogenates in a Na-free extraction buffer for
puriﬁcation using a method for conventional calpains [258].
Although full-length CAPN3 was detectable after running ﬁve col-
umns, the yield was too low to be used for biochemical studies.
CAPN3 is probably so “sticky” that it is largely absorbed by column
resins.
So far, no one has reported purifying intact, endogenous CAPN3
as an enzyme. To understand in vivo functions of CAPN3, we need to
investigate the quaternary structure, activity, and substrate speci-
ﬁcity of the native CAPN3 enzyme. This is a thorny but vital
research challenge. It is also important to consider both the
uniqueness and the commonality of CAPN3 as a calpain. CAPN3 has
versatile functions that are not restricted to skeletal muscles, and
this may be a common characteristic of calpain superfamily
members. The molecular mechanisms by which calpains achieve
their wide range of physiological functions are still elusive for the
most part. However, weak interactions of calpains with many
substrates may be a key feature in these mechanisms. To under-
stand diverse functions of CAPN3, the evolutionary viewpoint is
also indispensable. In this context, studies of non-mammalian
CAPN3s will be important [49].
Although CAPN3 is deﬁnitely a key regulator or gatekeeper of
sarcomeres [67,70], we must also remember that CAPN3 is a clas-
sical calpain belonging to the calpain superfamily. Many excellent
biochemical studies on other calpains have been published. The
CAPN3-LGMD2A ﬁeld is a rare and superb example of independent
biochemical and genetic studies that coincided 20 years ago, and
researchers are now cooperating to stimulate further discoveries
from both perspectives. Close cooperation between genetics
(including clinical genetics) and biochemistry research is essential
to further elucidate themysteries of this eccentric calpainmolecule.Acknowledgments
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